Teachers Retirement System of The State of Kentucky Invests $4.42 Million in Inari Medical, Inc. (NASDAQ:NARI)

Teachers Retirement System of The State of Kentucky bought a new position in Inari Medical, Inc. (NASDAQ:NARI – Get Rating) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 60,811 shares of the company’s stock, valued at approximately $4,418,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. California State Teachers Retirement System lifted its stake in shares of Inari Medical by 0.5% in the third quarter. California State Teachers Retirement System now owns 55,624 shares of the company’s stock worth $4,041,000 after buying an additional 279 shares in the last quarter. Retirement Systems of Alabama lifted its stake in shares of Inari Medical by 40.5% in the third quarter. Retirement Systems of Alabama now owns 62,908 shares of the company’s stock worth $4,570,000 after buying an additional 18,119 shares in the last quarter. Balyasny Asset Management LLC lifted its stake in shares of Inari Medical by 159.7% in the third quarter. Balyasny Asset Management LLC now owns 330,818 shares of the company’s stock worth $24,031,000 after buying an additional 203,418 shares in the last quarter. State Street Corp raised its holdings in shares of Inari Medical by 19.2% during the third quarter. State Street Corp now owns 1,552,608 shares of the company’s stock valued at $112,781,000 after purchasing an additional 249,751 shares during the last quarter. Finally, Pier Capital LLC raised its holdings in shares of Inari Medical by 1.5% during the third quarter. Pier Capital LLC now owns 100,603 shares of the company’s stock valued at $7,308,000 after purchasing an additional 1,533 shares during the last quarter. Institutional investors own 85.19% of the company’s stock.

Inari Medical Trading Down 2.6 %

Shares of NARI stock opened at $64.66 on Friday. Inari Medical, Inc. has a 12 month low of $50.50 and a 12 month high of $95.39. The stock has a market cap of $3.51 billion, a P/E ratio of -117.56 and a beta of 1.10. The company has a 50 day simple moving average of $59.34 and a two-hundred day simple moving average of $67.40.

Inari Medical (NASDAQ:NARI – Get Rating) last announced its earnings results on Monday, February 27th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.06. Inari Medical had a negative net margin of 7.63% and a negative return on equity of 7.03%. The business had revenue of $107.77 million during the quarter, compared to analysts’ expectations of $104.85 million. During the same period in the prior year, the company earned $0.02 earnings per share. The firm’s revenue was up 29.5% on a year-over-year basis. As a group, equities analysts forecast that Inari Medical, Inc. will post -0.51 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Morgan Stanley decreased their price objective on shares of Inari Medical from $95.00 to $83.00 and set an “overweight” rating for the company in a report on Friday, January 6th. Canaccord Genuity Group boosted their price objective on shares of Inari Medical from $77.00 to $80.00 and gave the company a “buy” rating in a report on Tuesday, February 28th. Finally, Truist Financial decreased their price objective on shares of Inari Medical from $75.00 to $65.00 and set a “hold” rating for the company in a report on Tuesday, January 31st. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Inari Medical presently has an average rating of “Moderate Buy” and a consensus price target of $88.56.

Insider Transactions at Inari Medical

In other news, Director William Hoffman sold 5,000 shares of the stock in a transaction on Tuesday, March 14th. The shares were sold at an average price of $60.10, for a total value of $300,500.00. Following the completion of the sale, the director now directly owns 1,252,540 shares of the company’s stock, valued at $75,277,654. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Director William Hoffman sold 5,000 shares of the stock in a transaction on Tuesday, March 14th. The shares were sold at an average price of $60.10, for a total value of $300,500.00. Following the completion of the sale, the director now directly owns 1,252,540 shares of the company’s stock, valued at $75,277,654. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Thomas Tu sold 10,000 shares of the stock in a transaction on Tuesday, December 27th. The stock was sold at an average price of $63.29, for a total transaction of $632,900.00. Following the completion of the sale, the insider now directly owns 86,451 shares of the company’s stock, valued at $5,471,483.79. The disclosure for this sale can be found here. Insiders sold a total of 146,250 shares of company stock valued at $9,236,348 over the last three months. Corporate insiders own 11.90% of the company’s stock.

About Inari Medical

(Get Rating)

Inari Medical, Inc, a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism.